Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
J Piccini, V Caso, S Connolly, K Fox, J Oldgren… - The Lancet, 2022 - hal.science
Background: Genetic variants in calsequestrin-2 (CASQ2) cause an autosomal recessive
form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated …
form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated …
[引用][C] Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox… - The …, 2022 - produccioncientifica.ucm.es
Background: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
[PDF][PDF] Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren… - Lancet, 2022 - core.ac.uk
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly… - Lancet (London …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
[引用][C] Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren… - LANCET, 2022 - pure.pmu.ac.at
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial
fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding …
fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox… - Lancet (London …, 2022 - europepmc.org
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren… - The Lancet, 2022 - Elsevier
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF). a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox, J Oldgren… - THE LANCET, 2022 - iris.uniroma1.it
Background: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …
JP Piccini, V Caso, SJ Connolly, KAA Fox… - THE …, 2022 - research.unipg.it
Background: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …